SQUARE

e-

SQUARE

 
Healthcare online Keeping you up-to-date
VOL.  7     ISSUE:  7    July 30, 2009 Medical Services Department

SQUARE Pharmaceuticals Ltd.

Features

EDITORIAL TEAM

OMAR AKRAMUR RAB

MBBS, FCGP, FIAGP,

P G Dip. Business Management

MAHFUZUR RAHMAN, MBBS

 

EDITORIAL

Dear Doctor,

Welcome to this edition of 'e-SQUARE'.

Our current issue focused on some interesting features like -
"
New Lab Test !", "Insulin & Breast Cancer !", "Biological Pacemaker !", "Baking Soda & Kidney Disease !",  "Facial Pain Alert !", "Antibiotic Risk !".

In our regular feature, we have some products information of SQUARE Pharmaceuticals Ltd. as well.

We will appreciate your feedback !

Click on to reply mode.

Yours sincerely,

 

Editorial Team

Reply Mode      : e-square@squaregroup.com

The views expressed in this publication do not necessarily reflect those of its editor or SQUARE Pharmaceuticals Ltd.

 New lab Test !

New Lab Test Predicts Kidney Damage

Acute kidney injury (AKI) is an ever-present danger to patients in intensive care. A new laboratory test called urine neutrophil gelatinase associated lipocalin (NGAL) helps predict if patients will develop acute kidney injury.  "As a stand-alone marker, urine NGAL performed moderately well in predicting ongoing and subsequent AKI," as per the researcher of the Vanderbilt University. Another study indicates that urine NGAL may also help diagnose HIV-related kidney disease affecting patients of African descent. "NGAL was very specifically expressed in renal cysts—generating the new idea that NGAL may control the development of cysts in HIV-associated nephropathy," according to the scientist of Columbia University, New York. In the ICU study, patients with higher urine NGAL levels were more likely to develop acute kidney injury, even after adjustment for other factors. The rise in NGAL was present before any change in the standard test for AKI. The scientist noted that the study was limited by a lack of information on incidence of death or the need for dialysis, and by a lack of information on the patients' initial kidney function level. In the HIV study, levels of urine NGAL were much higher in patients with HIV-associated nephropathy (HIVAN) than in patients with other forms of kidney disease, with or without HIV. HIVAN is an important complication of HIV, occurring mainly in patients of African descent. The researcher noted that the human component of their study was of limited size, and emphasizes the need for larger studies to definitively measure the NGAL monomer. He added that if their results are confirmed, measuring urine NGAL might help triage patients into different risk categories. 

SOURCE: Ivanhoe Newswire, July 2009.

Return to top

 Insulin & Breast Cancer !

Elevated Insulin Levels Linked To Breast Cancer

Postmenopausal women with elevated insulin levels may be at higher risk of developing breast cancer, a new study says. Researchers at Albert Einstein College of Medicine of Yeshiva University in New York City found a strong association between elevated insulin levels in the blood and increased risk of breast cancer. "Up to now, only a few studies have directly investigated whether insulin levels are associated with breast cancer risk," according to the lead author and senior epidemiologist in the department of epidemiology and population health at Einstein. Their study involved analyzing repeated measurements of insulin taken over several years -- which provides a more accurate picture of the possible association between insulin levels and breast cancer risk. The research team examined data on 5,450 women who took part in the Women's Health Initiative, a large study that looked at how various factors influence women's health. The researchers found that women with insulin levels in the highest third were twice as likely to develop breast cancer as women in the bottom third. The team also discovered that the link between elevated insulin levels and breast cancer was stronger for thin women than for obese women, who tend to have higher insulin levels. "This finding is potentially important because it indicates that, in postmenopausal women, insulin may be a risk factor for breast cancer that is independent of obesity," said the lead researcher. The study is ongoing, but the researcher recommended that postmenopausal women try to keep insulin at normal levels through weight loss, regular exercise and other methods.

SOURCE: HealthDay News, July 2009.

Return to top

 
 
 Biological Pacemaker !

Stem Cells Used For 'Biological Pacemaker'

Stem cells from a type of human fat tissue may one day be able to reverse the electrical problems in the heart that pacemakers now correct, Japanese scientists report.Researchers grew "beating" cells with properties similar to the heart's conductive tissue from stem cells taken from the brown fat tissue of mice. They then injected them into rodents with reduced heart rates caused by atrioventricular (AV) block.After a week, the AV block was completely reversed or partially reversed in half of the test mice. No change was observed in the control mice, the researcher said.The beating cells, which researchers colored green so they would be easy to see, were found to have attached near the section of the heart that manages its electrical conduction systems."Electronic pacemakers are often used as palliative therapy for people who have conduction problems with the electrical signals that govern the heart beat. However, that therapy has several shortcomings, including possible malfunction and the need for repeated replacement of the device's power packs and electrodes," according to the lead author at Chiba University Graduate School of Medicine in Chiba, Japan. "Cell therapy could overcome those problems and provide a possible cure for conductive disease. Our goal is to create a biological pacemaker," he added. Brown fat tissue is a source of mesenchymal stem cells, which previous studies have shown can develop into many different types of cells, such as bone, neuron, muscle, liver and fat cells. After isolating these cells in a laboratory, the Japanese team managed to grow groups of spontaneously beating cells. One tube-like group of cells resembled the heart's fine muscle fiber, while all contained two proteins, chemical markers and other similarities to the heart's own pacemaker-like cells.

SOURCE: HealthDay News, July 2009.

Return to top

 
 
 Baking Soda & Kidney Disease !

Baking Soda May Be Key Ingredient For Kidney Patients:  Study

A dose of baking soda a day may slow the progression of chronic kidney disease, a new study has found. The study included 134 advanced chronic kidney disease patients with metabolic acidosis, a condition caused by low bicarbonate levels. The patients were randomly divided into two groups, one of which took a small daily tablet of sodium bicarbonate (baking soda).The rate of kidney function decline was about two-thirds slower in the patients who took sodium bicarbonate than in other patients. Rapid progression of kidney disease occurred in 9 percent of patients taking sodium bicarbonate, compared with 45 percent in other patients, the researchers found. The study found that patients taking sodium bicarbonate showed improvement in several measures of nutrition, and, even though their sodium levels increased, there were no problems associated with higher blood pressure. These patients were also less likely to develop end-stage renal disease requiring dialysis. "This cheap and simple strategy has the potential of translating into significant economic, quality of life and clinical outcome benefits," said the researcher of Royal London Hospital in England. Low bicarbonate levels in patients with chronic kidney disease can lead to other health problems, and a simple remedy like sodium bicarbonate (baking soda), when used appropriately, can be very effective, the researcher added.

SOURCE: HealthDay News, July 2009.

Return to top

 
 
 Facial Pain Alert !

Drug Curbs Severe Facial Pain: Study

Results of a small study suggest that the drug pregabalin can reduce stabbing facial pain and other symptoms stemming from a condition called trigeminal neuralgia. The condition occurs in the trigeminal nerve, which affects perceptions of touch, pain and temperature in the face and jaw. People with trigeminal neuralgia experience shock-like or stabbing facial pain that may be triggered by everyday motions such as talking, tooth brushing or chewing. Few medications relieve the condition. Our findings suggest that pregabalin could be a first choice therapy when treating painful trigeminal neuralgia under 'real world' conditions, because it not only reduces the pain, but also its benefits extend to the associated symptoms of anxiety and depression and sleep disturbance-related symptoms -- in a well-tolerated fashion," the lead investigator said. The researcher of Hospital de La Princesa, Madrid and colleagues examined the effect of pregabalin in 65 patients with trigeminal neuralgia who had not received the agent before and had been resistant to previous analgesic therapy. Of this group, 36 received pregabalin alone and the remaining 29 used it in addition to their current therapy, mainly with non-steroidal anti-inflammatory drugs. Following 12 weeks of treatment, both groups showed a greater than 55% reduction in pain intensity. Almost 60% of responders showed pain reduction of more than 50%. There were also significant improvements in a variety of other measures, including a reduction in anxiety and depression and enhancement in sleep and in functioning. The team calls for further studies, but concludes that in spite of the small sample size, the results "support the effectiveness of pregabalin for the improvement in pain and related health symptoms." With pregabalin, doctors "have the opportunity to increase their options to clinically manage this condition, which is good news both for patients and physicians," the scientist added. Pregabalin gained U.S. regulatory approval last year to treat another pain condition called fibromyalgia.

SOURCE: Reuters Health, July 2009.

Return to top

 
 
 Antibiotic Risk !

Antibiotics May Boost Risk For Recurrent Ear Infection

Repeated use of antibiotics to treat acute ear infections in young children increases the risk of recurrent ear infections by 20 percent, according to researchers in the Netherlands who called for more prudent use of antibiotics in young children. The researchers found that 63 percent of children given the antibiotic amoxicillin experienced a recurrent ear infection within three years, compared with 43 percent of children given a placebo at the time of their initial infection. The finding came from a survey of parents of 168 children, 6 months to 2 years old, who took part in a study on the use of antibiotics to treat ear infections. In the group given amoxicillin, 47 out of 75 children had at least one recurrent ear infection, compared with 37 of 86 children in the placebo group. That equated to a 2.5 times higher risk of recurrent ear infection for the amoxicillin group. However, the study also found that 30 percent of children in the placebo group had ear, nose and throat surgery after their initial infection, compared with 21 percent in the amoxicillin group. The higher recurrence rate among children who took amoxicillin could be due to a weakening of their body's natural immune response as a result of taking an antibiotic at the initial stage of infection, the researchers said. Antibiotic use in such cases may cause an "unfavorable shift" toward the growth of resistant bacteria. Antibiotics may reduce the length and severity of the initial ear infection, but may also result in a higher number of recurrent infections and antibiotic resistance, the researchers stated. Because of this, they said, doctors need to be careful in their use of antibiotics in children with ear infections.

SOURCE: HealthDay News, July 2009.

Return to top

 
 

 Products of SQUARE Pharmaceuticals Ltd.

  Product Fexo® Suspension
  Generic Name Fexofenadine Hydrochloride USP
  Strength 30 mg/5 ml 
  Dosage form Suspension
  Therapeutic Category Systemic antihistamine
  Product Cadnyl® 4 Tablet  
Generic Name

Perindopril Erbumine BP

Strength 4 mg
Dosage form Film Coated Tablet
Therapeutic Category ACE inhibitor
  Product Flugal® 200 Capsule
  Generic Name Fluconazole USP
  Strength 200 mg
  Dosage form Capsule
  Therapeutic Category Systemic antifungal

Return to top

 

Copyright © 2009 SQUARE Pharmaceuticals Ltd. All rights reserved.